The market is flooded with ‘n‘ number of mediclaim policies, which confuse the investors. In an interview to CNBC-TV18, Harshvardhan Roongta, gives us more clarity on which mediclaim is best suited.
first published: Nov 22, 2012 01:02 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty extends gain for the third day, up nearly 2% this week | Closing Bell | 4K
From renewables to AI and SMEs: Madhusudan Kela on where he senses opportunity now
Will The Pre-Diwali Nifty Rally Rage On Amid Weak Global Cues? RIL Q2 in Focus | Opening Bell Live
Infosys Q2 Earnings Live | Decoding Infosys Q2 Earnings | Earnings Express
